De Botton S, Recher C, Cortes J, Curti A, et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. Br J Haematol 2025;206:1121-1128.
PMID: 39701584